The largest bottleneck medical research organisations at the forefront of technology face is access to useful data. These difficulties stem from strict policies that limit access to ML teams instead of allowing technology to enable and ensure responsible data use. Potential ML solutions are greatly stifled due to insufficient ability to access, standardise, and aggregate valuable data that continues to be siloed away. Yet, over the last years we have seen two general paradigms emerge to address important technical challenges.

This course is promoted by Champalimaud Foundation's Fior Lab.

The scientific programme will cover

- Protocols for preparation of human cancer cells for injection;
- Generation of zebrafish xenografts (microinjection in the perivitelline space);
- Metastatic assay;
- Protocols for immunofluorescence;
- Mounting xenografts for confocal imaging;
- Confocal session.

Venue

Champalimaud Center for the Unknown, Lisbon

Dates

06 - 10 May, 2024 - 9:00

Application

Deadline: March 15

But it isn’t only a skin cancer: there exist other, though much rarer, forms of malignant melanoma that can develop in other parts of the body.

For instance, mucosal melanoma occurs on mucous membranes, which line various cavities in the body. Mucosal melanomas can be found in the head and neck, the anorectal region, the vulvovaginal region and the urinary tract. These melanomas have a poorer prognosis than skin melanomas.

These two programmes provide students with an integrative, state-of-the-art education in either Neuroscience or Cancer. A central goal of these programmes is to foster inquiry and discovery by encouraging active participation, critical thinking, and problem-solving among the students.

Tânia Mesquita, 36, is responsible for the customer care area, for the clinical secretariat – and above all, for welcoming patients at the Champalimaud Clinical Centre (CCC). She has a degree in management, a master's degree in strategic marketing and a post-graduate degree in Health Unit Management.

This donation was officially formalised on November 23rd and was announced by Dr. Leonor Beleza, during the latest annual meeting of the Board of Trustees of the Champalimaud Foundation. The announcement took place in the presence of all board members, including Queen Sofia of Spain.

The funding provided by the Würth Group and the non-profit Würth Foundation is intended to support research into pancreatic cancer - a type of malignancy that persists as one of the most lethal, yet remains among the least explored.

For this edition of the contest, 11 groundbreaking biomedical and health projects spearheaded by research institutions and universities in Portugal were selected. This funding underscores the commitment of the “la Caixa” Foundation to champion projects of unparalleled excellence that stand to significantly benefit public health.

Listed below is more information about the seven awardees from the four COLife institutes and their projects.

O Curso terá lugar no dia 15 de dezembro, na Fundação Champalimaud, e oferecerá uma visão detalhada e atualizada sobre esta abordagem. Embora relevante para outras especialidades, este evento destina-se especialmente a médicos das áreas da Cirurgia, Oncologia Médica, Radiologia, Radioncologia e Gastrenterologia.

Artificial Intelligence is all around us, accelerating medical drug development, selecting what content we see across social media or outclassing us on the most human of tasks from driving to medical diagnoses. The transformational power of AI has the potential to alter our society as profoundly as the agricultural and industrial revolutions, but how did we get here?

What is intelligence, and why do we seek to replicate it artificially? 

When did the AI revolution begin, and can you recall your first encounter with AI? 

Pancreatic cancer is indeed a scary disease. This is because, when it becomes symptomatic enough to be detected and diagnosed, it has , in many cases, already disseminated, with  metastatic tumor cells invading other organs. 

Actually, it is among the most deadly forms of cancer, with an estimated five-year survival rate of around 3% once it has become metastatic, down from 44% when it is still localised, according to recent figures from the US National Cancer Institute.